CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Income Statement
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 | |||
| Operating Expenses | 210.74M | 201.06M | 178.14M | 212.26M | 153.63M | |||
| Research and Development | 161.03M | 150.24M | 124.41M | 155.08M | 95.66M | |||
| Selling, General, and Administrative Expenses | 49.71M | 50.81M | 53.73M | 55.20M | 42.89M | |||
| Operating Income | -195.74M | -201.06M | -171.28M | -212.26M | -153.63M | |||
| Interest Income/Expense | 8.88M | 3.93M | 570.00K | -7.03M | -1.17M | |||
| Other Income/Expense | 876.00K | -1.69M | -5.43M | 2.34M | -5.70M | |||
| Non Recurring Items | N/A | -34.10M | N/A | 0.00 | -220.45M | |||
| Income Before Taxes | -220.09M | -232.91M | -176.14M | -216.95M | -380.96M | |||
| Income Tax | 3.76M | 2.84M | -25.06M | -750.00K | 110.00K | |||
| Net Income | -223.85M | -235.76M | -151.09M | -216.21M | -381.07M | |||
| EBITDA | -194.82M | -200.11M | -170.47M | -212.13M | -153.60M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.80 | -2.05 | -1.56 | -2.30 | -5.05 | |||
| Non GAAP EPS | -1.55 | -1.73 | -1.57 | -2.31 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -1492.31% | N/A | -2204.65% | N/A | N/A | |||
| Operating Profit Margin | -1304.95% | N/A | -2499.39% | N/A | N/A | |||
All data in USD